MicuRx Pharmaceuticals has received a US patent from the USPTO covering the composition of its clinical candidate, MRX-I.
The antibacterial oxazolidinone targets infections due to multi-drug resistant Gram-positive pathogens.
MicuRx president and chief executive officer Zhengyu Yuan said, "With a scarcity of new antibiotics in development and ever-increasing bacterial resistance, we believe that MRX-I, with its high antimicrobial potency and enhanced safety profile, could offer a valuable option for treatment of infections caused by multi-drug resistant Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE)."
MicuRx's agents directly address the problem of multi-drug resistant bacteria, with a potential for deployment in both hospital and community-based settings, the company said.